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Abstract 
Background: The aim of this prospective, randomized, placebo-controlled study was to 
compare the effects of ketamine and paracetamol on preventing remifentanil induced hy-
peralgesia.  
Methods: Ninety patients undergoing total abdominal hysterectomy were randomly assigned 
to one of three groups to receive (I) either saline infusion; (II) 0.5 mg/kg ketamine iv bolus or 
(III) 1000 mg iv paracetamol infusion before induction of anesthesia. Until the skin closure, 
anesthesia was maintained with 0.4 µg/kg/min remifentanil infusion in all groups, additionally 
Group II received 5 µg/kg/min ketamine infusion. Pressure pain thresholds were measured the 
day before surgery during the preoperative visit for baseline measurements and repeated 
postoperatively at 24
 and 48
 hours (hrs). Pressure pain thresholds were established by digital 
algometer  on  three different  peri-  incisional  regions for calculating mean  pressure  pain 
threshold values. The visual analogue scale (VAS), sedation scores, total morphine con-
sumption and side effects were assessed postoperatively. 
Results: Demographic characteristics, duration of surgery and anesthesia were similar in the 
three groups. Pain thresholds at the incision region were significantly lower at 24 and 48 hrs 
postoperatively in Group I than the other Groups (p< 0.05). In Group І, pain thresholds were 
lower compared with preoperative baseline values. Thresholds in Group ІІ and Group ІІІ 
were higher compared with preoperative baseline values (p< 0.05) The VAS scores at all 
evaluation times were significantly higher in Group І when compared to Group ІІ and at 2, 4, 
6
 ,12 hrs were higher in Group I than Group ІІІ (p< 0.05). The morphine consumption was 
higher in Group ІІІ at 24 and 48 hrs postoperatively (p< 0.05). 
Conclusion: It was shown that ketamine and paracetamol were both effective in preventing 
remifentanil induced hyperalgesia. 
Key words: remifentanil, ketamine, paracetamol, postoperative pain, hyperalgesia. 
Introduction 
Opioids are potent analgesics that are often nec-
essary for treating moderate to severe pain. However, 
experimental  studies  report  that  opioids  may  also 
elicit hyperalgesia and allodynia (1). It is, therefore, 
likely  that  tolerance  develops  more  rapidly  with  a 
rapid  offset  drug  such  as  remifentanil  than  with 
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longer acting opioids (2). The most likely explanation 
for  the  greater  postoperative  analgesic  requirement 
for remifentanil is development of acute opioid tol-
erance  to  morphine  analgesia  (3).  Opioid-induced 
processes  that  underlie  hyperalgesia  reduce  antino-
ciception and contribute to opioid tolerance (4-6).  
 Among  the  potential  mechanisms  leading  to 
opioid induced hyperalgesia and antinociceptive tol-
erance,  N-methyl-D-aspartate  (NMDA) 
pain-facilitator  processes  seem  to  play  a  key  role 
(1,7,8).  Experimental  studies  performed  in  animals 
and volunteers have shown that NMDA receptor an-
tagonists such as ketamine inhibit central sensitization 
and prevent opioid induced hyperalgesia (9-12).  
 The  analgesic  and  antihyperalgesic  actions  of 
cyclooxygenase  (COX)  inhibitors,  the  so-called 
non-steroidal  anti-inflammatory  drugs  (NSAIDs), 
have traditionally been attributed to inhibition of pe-
ripheral  prostaglandin  (PG)  synthesis  in  inflamed 
tissue (13). However, there is increasing evidence that 
at least part of their analgesic effects depends on COX 
inhibition  in  the  central  nervous  system  (14).  Both 
isoforms are constitutively expressed in the rat brain 
and spinal cord (15). Recently, a third distinct isoform, 
COX-3, has been described, which is a spliced COX-1 
variant  and  is  suggested  to  represent  the  primary 
central  mechanism  by  which  paracetamol  (aceta-
minophen) decreases pain and possibly fever (13). In 
the  last  decade,  several  peripheral  antihyperalgesic 
actions of NSAIDs have been demonstrated in human 
models of mechanical and heat hyperalgesia (16). In 
rats, there is also evidence for COX-induced central 
sensitization. Also, in humans, the rapid onset of an-
algesic effects of COX-2 inhibitors after brief surgical 
intervention suggest a central antihyperalgesic effect, 
but  direct  evidence  for  this  action  is  still  lacking 
(15,17).  
In humans, opioid tolerance, the analgesic effects 
of  opioids  and  opioid  requirements  are  evaluated 
with a quantitative sensorial test (QST) (18-20). It was 
shown that ketamine prevented postoperative hyper-
algesia induced by remifentanil (1). However, we did 
not  find  the  effects  of  paracetamol  on  remifentanil 
induced  hyperalgesia  in  the  postoperative  setting. 
Therefore, we planned to test the effects of paraceta-
mol on remifentanil-induced hyperalgesia and com-
pare these with ketamine, which has been shown to 
prevent remifentanil-induced hyperalgesia, by using 
postoperative pain scores, opioids consumption and 
quantitative sensorial test. 
 Materials & Methods 
After receiving approval from Ethical Commit-
tee  of  Selcuk  University  Meram  Medical  Faculty, 
Konya,  Turkey  (Ethical  Committee  B.30.2.SEL. 
002.0081-2917,  30  April  2008)  and  written  informed 
consent, we enrolled 90 patients of ASA physical sta-
tus  I–II  scheduled  for  elective  total  abdominal  hys-
terectomy  by  using  a  computer-generated  random 
number system. Patients with a history of psychiatric 
disorders, chronic pain, renal, cardiac or hematologi-
cal  insufficiency,  chronic  analgesic  or  opioid  treat-
ment, aged below 35 yr and above 70 yr, inability to 
use a patient-controlled analgesia (PCA) device and 
duration of surgery over 120 min were excluded from 
the study. During the preoperative visit, the day be-
fore surgery, all patients were instructed in the use of 
the 10-step visual analogue scale (VAS; 0 = no pain, 10 
= greatest imaginable pain), PCA device (Abbott Pain 
Management  Provider,  Chicago),  and  quantitative 
sensory  tests  (QST)  applied  with  a  digital  pressure 
algometer  (Chatillon  DFE-100,  Digital  Force 
Gauge/AMETEK)  by  an  anesthesiologist.  Addition-
ally, baseline values for QST on skin area of surgery 
were performed. A handheld digital pressure algom-
eter with a 1 cm2 probe area was used to determine 
pressure  pain  threshold.  The  patients  informed  the 
researcher  when  pain  was  perceived  and  the  re-
searcher immediately pushed a button to freeze the 
digital display. The first pressure value at which pain 
was registered was saved as Lb unit value. The aver-
age of three measurements with an interstimulus in-
terval  of  60  s  was  defined  as  the  pressure  pain 
threshold  value.  Pressure  pain  thresholds  were 
measured in an area 2–3 cm from the incision at three 
levels (top, middle, and bottom; baseline values) and 
on the inner forearm (control values). A mean value 
for  the  three  peri-incisional  regions  was  calculated 
and used for statistical comparisons. The, QSTs were 
repeated at 24 and 48 hours postoperatively.  
All patients were premedicated with 10 mg oral 
diazepam the night before surgery and 10 mg intra-
muscular diazepam one hour before surgery. Patients 
were randomly assigned to one of the three groups 
using a computer-generated random numbers. Base-
line  heart  rate,  systolic  (SAP),  diastolic  (DAP)  and 
mean arterial pressure (MAP) were recorded before 
induction of anesthesia and at 15 min intervals during 
surgery. Patients in Group I received physiologic sa-
line; whereas those in Group II received intravenous 
(iv) bolus ketamine 0.5 mg/kg, and those in Group III 
received 1000 mg paracetamol (infusion/15 min) be-
fore  the  induction  of  anesthesia.  The  patients  in 
Group  II  also  received  a maintenance  infusion  of  5 
µg/kg/min ketamine intraoperatively until skin clo-
sure.  
 General anesthesia was induced with remifen-
tanil 1 µg/kg and propofol 1.5-2 mg /kg followed by Int. J. Med. Sci. 2012, 9 
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atracurium 0.5 mg/kg to facilitate tracheal intubation. 
Anesthesia  was  maintained  with  0.4  µg/kg/min 
remifentanil infusion and desflurane 0.5 MAC. Lungs 
were mechanically ventilated (end-tidal CO2 values 
of 35-40 mmHg) with 50% air in an oxygen mixture. 
All patients in the three groups had received the same 
anesthesia  regimen.  Insufficient  anesthesia  was  de-
fined as a heart rate that exceeded pre-induction val-
ues  by  15%  and  SAP  exceeding  baseline  values  by 
20% for at least 1 min. Patient movement, coughing, 
tearing and sweating were also considered signs  of 
inadequate  anesthesia.  Inspired  desflurane  was  in-
creased stepwise by 1% MAC when insufficient an-
esthesia  was  suspected.  Hypotension,  defined  by  a 
MAP  less  than  60  mmHg,  prompted  stepwise  1% 
MAC  reductions  in  desflurane.  If  bradycardia  and 
hypotension persisted, additional iv fluids, atropine 
and ephedrine were also given. Thirty minutes before 
the anticipated end of surgery, a 0.15 mg/kg bolus 
dose of morphine was given intravenously.  
After skin closure, desflurane, remifentanil and 
ketamine  infusion  were  discontinued,  and  residual 
neuromuscular  blockade  was  reversed  by  0.04-0.08 
mg/kg iv neostigmine and 0.02-0.04 mg/kg iv atro-
pine.  The  trachea  was  extubated  when  patients  re-
sponded to the verbal commands, spontaneous res-
piratory rate exceeded 12 breaths/min, and end-tidal 
carbon  dioxide  partial  pressure  was  less  than  45 
mmHg. The times from the remifentanil discontinua-
tion until awakening (awakening time) and tracheal 
extubation (extubation time) were recorded.  
When patients responded to verbal commands, 
the first postoperative VAS was taken and noted as 
VAS  0  hr.  Another  observer,  who  was  unaware  of 
patients’ group assignments, evaluated patients dur-
ing the postoperative period. When  VAS score was 
less than 5, patients were connected to a PCA device 
set to deliver 1 mg morphine as an iv bolus with a 
6-min lockout interval; continuous infusion was not 
allowed. This PCA regimen was continued for 48 hrs 
after  tracheal  extubation  and  other  analgesics  were 
not used during this period. The VAS scores, analge-
sic demand, analgesic delivery, morphine consump-
tion  and  sedation  scores  (1:  patient  fully  awake,  2: 
patient occasionally asleep, 3: patient often sleep but 
awakening  easily  4:  difficulty  awakening,  5:  not 
awakening) were recorded at 2, 4, 6, 12 and 24 hrs 
postoperatively.  Any  adverse  postoperative  effects, 
such as nausea-vomiting, nightmare, diplopia, hallu-
cination or agitation were noted. The satisfaction with 
analgesia of the patients was graded on a four-point 
scale (1-4) as follows: 1, poor; 2, intermediate; 3, good; 
4, excellent.  
Statistical Analysis 
All  analyses  were  conducted  using  SPSS  soft-
ware (Statistical Package for the Social Sciences, ver-
sion 13.0, SPSS Inc, Chicago, IL, USA). Data was re-
ported as mean ± standard deviation and the number 
n (%). One-way ANOVA (analysis of variance) was 
used  for  comparison  between  groups.  Paired 
group-wise tests were performed to find groups that 
make a difference. Kruskal Wallis analysis was per-
formed for the variables which were not included in 
the variance analysis. P values < 0.05 were considered 
significant.  
Results 
Ninety  patients  were  enrolled  in  the  study. 
Eleven patients were excluded due to postoperative 
fever,  duration  of  surgery  and  non-cooperation. 
Twenty-seven  patients  were  randomly  assigned  to 
Group І (control), twenty-six to Group ІІ (ketamine) 
and  twenty-six  to  Group  ІІІ  (paracetamol).  Demo-
graphic  characteristics,  duration  of  surgery  and  an-
esthesia were similar in the three treatment groups. 
Awakening time and extubation time were compared 
in the three groups, and they were significantly longer 
in Group II than other groups. (p< 0.05) (Table 1).  
Intraoperatively  desflurane  requirement,  SAP, 
DAP, MAP and heart rate were similar in the three 
groups. Three patients in Group І, one in Group ІІ and 
three in Group ІІІ required 0.5 mg atropine treatment 
(p > 0.05).  
 
 
 
Table 1. Patient characteristics and intraoperative varia-
bles. Values are shown as number of patients or mean ± SD. 
Groups  Group І (n = 27) Group ІІ (n = 
26) 
Group ІІІ (n= 
26) 
Age (yr)  48.14 ± 5.98  48.26 ± 5.66  47.2 ± 5.59 
Weight (kg)  70.29 ± 11.5  73.34 ± 8.80  76.92 ± 7.89 
ASA–PS I/II/III 
(n) 
18/7/2  19/6/1  16/9/1 
Duration of 
anesthesia (min) 
80.55 ± 13.14  80.00 ± 13.41  80.38 ± 13.26 
Duration of 
surgery (min) 
70.55 ± 12.14  70.00 ± 13.41  70.38 ± 13.26 
Extubation time 
(sec) 
243.26 ± 64.01  317.42 ± 75.24*  265.61 ± 60.46 
Awakening time 
(sec) 
260.44 ± 62.20  413.30 ± 26.88*  282.23 ± 57.18 
* p< 0.05 (Comparison between groups) 
ASA-PS American Society of Anesthesiologists physical status 
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Figure 1. Postoperative VAS values of the Groups (mean±SD). * 
p< 0.05; Group I vs Group II; † p< 0.05; Group I vs Group III. 
 
Pain VAS scores at 0, 2, 4, 6, 12 and 24 hrs post-
operatively were assessed in all groups (Figure 1). The 
VAS scores at all evaluation times were significantly 
higher  in  Group  І  when  compared  to  patients  in 
Group ІІ and at 2, 4, 6 ,12 hrs were higher in Group I 
than Group ІІІ (p < 0.05). The VAS scores between 
Group ІІ and Group ІІІ were similar (p > 0.05).  
At all of the postoperative evaluation times, an-
algesic delivery was higher in Group І compared to 
Groups  ІІ  and  ІІІ.  Patients'  analgesic  delivery  was 
significantly  higher  at  the  2,  12,  24  and  48  hrs  in 
Group ІІІ than Group ІІ (p< 0.05) (Table 2). Analgesic 
demand  was  significantly  lower  in  Group  ІІ  com-
pared  to  Groups  І  and  ІІІ  (Table  3).  Analgesic  re-
quirements were significantly higher in Group І at all 
times than Group ІІ and at 4, 6, 12, 24 and 48 hrs than 
Group ІІІ (p < 0.05). Cumulative 24 and 48 hrs mor-
phine  consumption  was  higher  in  Group  ІІІ  than 
Group ІІ (35.34±13.71mg at 24 hr and 42.52±15.08 mg 
at  48  hr  in  Group  II;  48.53±12.40  at  24  hr  and 
57.11±16.71 mg at 48 hr in Group III) (p < 0.05).  
 There  were  no  significant  differences  between 
the Groups in terms of pain thresholds assessed with 
an algometer at 24 and 48 hrs and preoperatively on 
inner forearm. Pain thresholds at the incision region 
were significantly lower at 24 and 48 hrs postopera-
tively in Group I than in the other two Groups (p < 
0.05).  In  Group  І  pain  thresholds  were  lower  com-
pared with pre-operative baseline values; in Group ІІ 
and Group ІІІ pain thresholds were higher compared 
with pre-operative baseline values (p < 0.05) (Figure 
2).  
 With respect to satisfaction scores, the patients 
in Group II and Group III were more satisfied than 
those in Group I and it was found to be statistically 
significant (p< 0.05) (Table 4). The incidences of nau-
sea, vomiting and need for antiemetic treatment were 
similar  in  all  groups.  With  respect  to  postoperative 
ketamine psychopharmacologic effects, two patients 
reported nightmare at 24 and 48 hrs after surgery and 
seven patients reported diplopia at 24 hrs. Sedation 
scores were similar in all groups but was higher in 
Group II only at postoperative 2nd hr. (Figure 3). 
 
 
Table 2. Analgesic delivery (mg of morphine consumption 
of the patients; the amount of infused and bolus doses of 
morphine with PCA device) of the patients. Values are 
shown as mean ± SD. 
Evaluation 
Times (hr) 
Group І (n = 27) Group ІІ (n = 
26) 
Group ІІІ (n= 
26) 
2  15.66±2.63*  12.15±3.0  14.03±3.56 
4  26.11±4.57*†  18.46±6.54  21.8±6.13 
6  36.7±7.16*†  23.53±8.96  28.15±8.36 
12  57.07±15.49*†  30.92±12.19  39.34±11.50 
24  73.03±22.41*†  35.34±13.71‡  48.53±12.40 
48 (Total mor-
phine dose) 
86.05±29.46*†  42.52±15.08‡  57.11±16.71 
* p< 0.05 (Group I vs Group II) 
† p< 0.05 (Group I vs Group III) 
‡ p< 0.05 (Group II vs Group III) 
 
 
Table 3. Analgesic demand (presses to the button of the 
PCA for delivery of morphine ) of the patients. Values are 
shown as mean ± SD. 
Evaluation 
Times (hr) 
Group І (n = 27) Group ІІ (n = 
26) 
Group ІІІ (n= 
26) 
2  32.85±8.19*†  23.0±7.08  28.69±7.01 
4  53.03±12.19*†  32.84±11.83  39.34±9.02 
6  70.81±15.03*†  40.61±15.56  49.11±11.70 
12  102.44±27.49*†  52.19±20.40  66.73±16.14 
24  134.59±41.07*†  60.11±23.74‡  92.69±20.44 
48  146.19±21.2*†  73.20±15.63‡  104.81±14.57 
* p< 0.05 (Group I vs Group II) 
† p< 0.05 (Group I vs Group III) 
‡ p< 0.05 (Group II vs Group III) 
 
 
 
Table 4. Satisfaction scores of the patients. Values are 
shown as number of patients and percentage median. 
Satisfaction 
Score 
Group І (n %)  Group ІІ (n %)  Group ІІІ (n %) 
1  0 (0%)  0 (0%)  0 (0%) 
2  1 (3.7%)  0 (0%)  0 (0%) 
3  14 (51.85%)  2 (7.7%)  4 (15.4%) 
4  12 (44.4%)  24 (92.3%)*  22 (84.6%)* 
* p< 0.05 (Comparison between groups) Int. J. Med. Sci. 2012, 9 
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Figure 2. Mean Pressure Pain Thresholds (Lb) determined with digital pressure algometer on inner forearm and the surgical incision area 
at preoperative period and than postoperative 24th and 48th h (mean±SD ). * p< 0.05; Group I vs Group II; † p< 0.05; Group I vs Group 
III; ‡ p< 0.05; Group II vs Group III. 
 
 
Figure 3. Postoperative Sedation Scores of the Groups (mean±SD). * p< 0.05 (Comparison between groups) 
 
Discussion  
The  half-life  of  remifentanil  is  too  short  and 
therefore remifentanil is recommended for use as an 
infusion and is widely used as an important part of 
general anesthesia (3). Since the effect of duration is 
short, it is recommended to use additional analgesics 
before  surgery  ends  to  prevent  postoperative  pain. 
However,  in  these  cases,  earlier  and  more  frequent 
use of first dose postoperative analgesic is connected 
to acute opioid tolerance (2, 11,21). In a study by Joly 
et  al.  using  low  (0.05  mg/kg/min)  and  high  (0.4 
mg/kg/min)  doses  of  remifentanil,  morphine  con-
sumption  was  higher  in  the  high  dose  remifentanil 
group (1). This situation has been linked to develop-
ment of rapid acute opioid tolerance and it is empha-
sized  that  the  dose  of  remifentanil  used  was  im-
portant (1). In line with this data, the current study 
used remifentanil at the dose of 0.4 mg/kg/min in 
order to better evaluate of the effectiveness of para-
cetamol and ketamine.  
In hyperalgesia due to opioids, there is a rela-
tionship  between  reduction  of  antinociception  and 
opioid tolerance (4-6,9). Under the guidance of poten-
tial  mechanisms  between  antinociceptive  tolerance 
and opioids induced hyperalgesia, NMDA is seen to Int. J. Med. Sci. 2012, 9 
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play a key role in processes facilitating on pain (8). In 
experimental studies with volunteers, NMDA recep-
tor antagonists such as ketamine inhibit central sensi-
tization and have been shown to prevent opioid con-
nected  hyperalgesia  (9-12).  It  was  shown  that  low 
dose ketamine (0.5 mg/kg bolus and 0.5 mg/kg/min) 
when added to remifentanil, prevented remifentanil 
induced hyperalgesia (1). In line with this data, we 
elected to add low-dose ketamine (0.5 mg/kg bolus 
and 0.5 mg/kg/min infusion) to remifentanil infusion 
in our study.  
Tolerance  of  opioids  and  hyperalgesia  were 
evaluated  with  analgesic  effect,  opioid  needs  and 
quantitative sensory tests in several studies (9,18-20). 
QST,  clinical  and  sensory  evaluation  are  important 
experimental tools. In our study, postoperative pain 
scores and morphine consumption was characterized 
by  an  increase  in  hyperalgesia.  The  pressure  pain 
threshold were assessed with digital pressure algom-
eter. 
In the current study, VAS scores were found to 
be  significantly  better  in  the  ketamine  group  than 
control  group  and  in  accordance  to  this,  morphine 
consumption was also found to be less than the con-
trol  group.  Decreased  hyperalgesia  was  detected  in 
the sensory test with a digital algometer, conducted at 
24 and 48 hrs postoperatively in Group ІІ. Joly et al. 
used the same dose of remifentanil and ketamine as 
used in the present study, but pain scores and hyper-
algesia in their study were not affected (1). We could 
explain  this  difference  with  the  first  bolus  dose  of 
ketamine use before the induction and use prior to the 
opioid implementation. Jaksch et al (22) used the same 
bolus  dose  of  ketamine  before  the  induction  as  we 
have implemented, but in their study postoperative 
pain were not affected. This is another different result 
from our study, and we believe his may be related to 
the high infusion dose usage in our study. 
The  peripheral  anti-inflammatory  and  antihy-
peralgesic effects of NSAIDs have been shown in ex-
perimental and clinical studies (13, 23). Despite a large 
number of experimental studies related to central an-
tihyperalgesic effects, there is a very limited number 
of clinical studies (13). In a study of central hyperal-
gesia models in rats, Bianchi and Paneri (24) evaluat-
ed the antihyperalgesic effects of lornoxicam, piroxi-
cam and meloxicam, which have the same chemical 
structure but different COX-1 and COX-2 selectivities. 
All showed the same anti-inflammatory effect, did not 
cause changes in thermal nociceptive threshold, and 
significantly  reduced  hyperalgesia.  However,  only 
lornoxicam has been reported to be fully effective in 
prevention  of  hyperalgesia.  The  difference  between 
anti-inflammatory  and  antihyperalgesic  activities  of 
NSAIDs  and  with  the  blocking  of  both  COX-1  and 
COX-2  antihyperalgesic  activity  to  be  significantly 
reported  (24).  Peripheral  inflammation,  increased 
levels of spinal PG's, spinal PGE2, largely involved in 
the  spinal  nociceptive  process  and  the  increase  in 
PGE2 concentration was shown to be correlated with 
hyperalgesia (24).  
Different results have been reported on the an-
tihyperalgesic effects of COX-3 inhibitors assumed as 
COX-1 variants and centrally effective paracetamol. In 
a study of volunteers, the antihyperalgesic effect of 
paracetamol (1000 mg) was evaluated and was shown 
to reduce secondary hyperalgesia field (13). In another 
study on volunteers, no antihyperalgesic effect of pa-
racetamol (1000 mg) was reported (25). We did not 
come across a study evaluating the efficacy of para-
cetamol in preventing hyperalgesia due to intraoper-
ative use of remifentanil. Therefore, in this study, pa-
racetamol  activity  was  compared  with  ketamine, 
supported by clinical studies, to prevent remifentanil 
induced  hyperalgesia.  We  showed  that  VAS  scores 
and  morphine  consumption  was  less  in  both  the 
ketamine  and  paracetamol  group.  Additionally,  re-
duced hyperalgesia was detected in the sensory test 
performed  by  digital  algometer  at  24  and  48  hrs 
postoperatively. These results show that paracetamol 
is  also  effective  in  preventing  remifentanil  induced 
hyperalgesia  in  humans,  which  has  been  known  to 
contribute to secondary hyperalgesia.  
The most important factor limiting the use of in-
traoperative and postoperative agents is undesirable 
effects. Ketamine may extend the period of awaken-
ing and extubation, may cause bad dreams, double 
vision, hallucinations, and agitation. It is also associ-
ated with dose-dependent incidence of side effects. In 
small doses (< 10 mg/hr), cognitive functions are not 
affected  (26).  In  our  study,  in  the  ketamine  group, 
during the early postoperative period, 7 patients had 
diplopia and 2 patients experienced bad dreams. The 
incidence  of  nausea  and  vomiting  was  similar  be-
tween groups. Extubation  and awakening time was 
longer  in  the  ketamine  group.  Early  postoperative 
sedation scores were higher in the ketamine group. 
The psychotomimetic reactions were not observed in 
the current study because of using low doses of ket-
amine. These low levels of ketamine do not usually 
cause side effects. We did not see any side effect as-
sociated with the use of paracetamol. Patient satisfac-
tion  was  higher  in  the  ketamine  and  paracetamol 
groups. We believe these results are based on better 
VAS scores.  
In this study, we evaluated the effect of preemp-
tive  1000  mg  paracetamol  on  remifentanil-induced 
hyperalgesia  in  comparison  with  ketamine.  In-Int. J. Med. Sci. 2012, 9 
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traoperative  hemodynamic  parameters  were  not  af-
fected  and  no  significant  change  in  desflurane  con-
centration  was  seen  than  ketamine  group.  In  the 
postoperative period, pain scores and morphine con-
sumption  were  lower  in  both  the  paracetamol  and 
ketamine group.  
In  conclusion,  concerning  the  effects  of  the 
drugs, paracetamol is as effective as ketamine in pre-
venting hyperalgesia caused by the use of intraopera-
tive remifentanil. Further studies comparing parace-
tamol with other drugs that have been shown to pre-
vent opioid induced hyperalgesia are needed to con-
firm our results. 
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